S-1 and cpt-11 plus ramucirumab (Iris+rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer (mcrc): A multicenter phase ii study in japan (n-docc-f-c-1701)

Abstract

This CPT-11+S-1multicenter phase II N-DOCC-F-C-1701 trial is being planned in order to investigate the efficacy and safety of +Ramucirumab (IRIS+Rmab), which is anticipated to have a stronger anti-tumor effect than IRIS+Bmab in patients with metastatic colorectal cancer (mCRC) previously treated with oxaliplatin (L-OHP) containing regimen, in consideration of the result of RAISE, FIRIS and some phase II trials of IRIS+Bevacicizumab (Bmab). The number of patients is set at 38 for the statistical analysis, assuming an expected median PFS of 5.0 months (threshold: 3.0 months). The primary endpoint of the study is the progression free sur-vival (PFS), and the secondary endpoints are the overall response rate (ORR), overall survival (OS), adverse events (AE), quality of life (QOL) and review of nausea and vomiting. This trial is registered in the UMIN Clinical Trials Registry as UMIN000028170. We intend to start conducting the trial in September 1, 2017. If this trial meets the endpoint, IRIS+Rmab might be supported as a new optional standard regimen for mCRC.